January 15, 2015
Eli Lilly Japan and Nippon Boehringer Ingelheim (NBI) won approval for the biosimilar insulin products Insulin Glargine BS Injection Cart “Lilly” and Insulin Glargine BS Injection MirioPen “Lilly” (original product: Lantus from Sanofi) on December 26 last year, the companies...read more